Empirical Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-73,041
Closed -$2.3M – 1172
2026
Q2
$2.3M Buy
73,041
+6,818
+10% +$201K 0.03% 248
2026
Q1
$1.64M Buy
66,223
+8,673
+15% +$207K 0.03% 274
2025
Q4
$1.34M Buy
57,550
+5,394
+10% +$120K 0.02% 293
2025
Q3
$1.03M Buy
+52,156
New +$1.07M 0.02% 323
2022
Q2
– Sell
-24,534
Closed -$203K – 477
2022
Q1
$203K Buy
24,534
+12,524
+104% +$88.5K 0.01% 472
2021
Q4
$81K Buy
+12,010
New +$79K ﹤0.01% 509

Other funds holding CPRX

Empirical Wealth Management's CPRX Position: Q3 2026 in Review

Empirical Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 73,041 shares — an estimated $2.3M sold.

Empirical Wealth Management first reported a position in CPRX in Q4 2021 and held it in 6 quarters. The position peaked at $2.3M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Empirical Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Empirical Wealth Management sold 73,041 Catalyst Pharmaceutical shares in Q3 2026, an estimated $2.3M.
  • Empirical Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 6 quarters.
  • Empirical Wealth Management's Catalyst Pharmaceutical position peaked at $2.3M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Empirical Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.